Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

The CRISPR company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Intellia (NTLA) said it plans to focus on developing NTLA-2002 and nex-z and discontinue development of NTLA-3001, which will result in the company cutting 27% of its workforce.

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) yesterday and set a price target of ...

Intellia Therapeutics (NTLA) announced a strategic reorganization focused on key value drivers. The pipeline prioritization is intended to ...

Despite the market's response to the reorganization and workforce reduction, Intellia ended the fourth quarter of 2024 with a strong cash position of approximately $862 million. This financial ...

Intellia Therapeutics will cut about 27% of its workforce, or roughly 142 jobs, this year in a cost-savings push intended to support its operations into the first half of 2027, when it expects to ...

Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the company announced a strategic ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

The stock market will put aside all fears about tariffs and valuations this morning. The job data in December, released by the Bureau of Labor Statistics will give investors a clue on the U.S. economy ...